Testing
Fewer than one in four patients with elevated Lp(a) had their lipid-lowering therapy intensified within 30 days (J Clin Lipidol 2025)
Original title: Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels
This retrospective case-control study examined changes to lipid-lowering therapy in patients with an Lp(a) value of 30 mg/dL (75 nmol/L) or higher between January 2020 and May 2024. Of 1,042 patients with a qualifying elevated Lp(a) result, 539 met full inclusion criteria, and only 120 (22.3%) had their lipid-lowering therapy modified within 30 days of the result. Among those whose therapy was changed, adding ezetimibe (33.3%) and intensifying statin therapy (32.5%) were the most common interventions. Elevated LDL cholesterol, not the Lp(a) result itself, was the strongest predictor of whether medication was modified, consistent with current guidance to manage elevated Lp(a) risk by intensifying LDL-lowering. The findings expose a substantial gap between elevated Lp(a) results and actual changes in clinical management, and the authors call for future study of whether aggressive LDL-C lowering is as effective as direct Lp(a) lowering for ASCVD prevention.
Original abstract
Background: Elevated lipoprotein(a) (Lp(a)) is a recognized independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular-related disorders. To mitigate the increased risk associated with elevated Lp(a), intensified treatment is recommended for modifiable ASCVD risk factors, such as hypertension, hyperglycemia, and dyslipidemia. However, limited evidence has assessed how clinicians are modifying lipid-lowering therapy in response to elevated Lp(a) levels.
Objective: To evaluate changes to lipid-lowering therapy and assess which patient characteristics are associated with intensifying lipid-lowering medications.
Methods: This retrospective, observational case-control study evaluated changes to lipid-lowering therapy in patients with elevated Lp(a) values from January 1, 2020, through May 31, 2024.
Results: Of 1042 patients with an Lp(a) value of 30 mg/dL (75 nmol/L) or higher during our study period, 539 met full inclusion eligibility. Of the 539 patients, 120 (22.3%) had their lipid-lowering therapy modified within 30 days of the elevated Lp(a) result. The most common interventions were adding ezetimibe (33.3%) and intensifying statin therapy (32.5%). Elevated low-density lipoprotein cholesterol (LDL-C) was the most significant predictor of whether patients' lipid medications were modified, concordant with current recommendations for mitigating increased ASCVD risk associated with elevated Lp(a).
Conclusion: Intensification of lipid-lowering medication within 30 days occurred in less than one-quarter of patients with elevated Lp(a). Future studies are needed to determine if aggressive LDL-C lowering is superior to Lp(a)-lowering to prevent ASCVD events in patients with elevated Lp(a).
Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.